{"nctId":"NCT02623998","briefTitle":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","startDateStruct":{"date":"2016-07-09","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":102,"armGroups":[{"label":"Intervention","type":"EXPERIMENTAL","interventionNames":["Drug: insulin glargine","Drug: sitagliptin/metformin","Behavioral: lifestyle therapy"]},{"label":"Standard Care","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"insulin glargine","otherNames":["Lantus"]},{"name":"sitagliptin/metformin","otherNames":["Janumet"]},{"name":"lifestyle therapy","otherNames":["diet and exercise"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. men and women 30-80 years of age inclusive;\n2. type 2 diabetes mellitus diagnosed by a physician within 5 years prior to patient enrollment;\n3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization;\n4. HbA1C ≤ 9.5% on no oral hypoglycemic agents or HbA1C ≤ 8.0% on 1 oral agent or on half-maximal doses of 2 agents;\n5. body mass index ≥ 23 kg/m2;\n6. a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential;\n7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG); ability and willingness to self-inject insulin;\n8. provision of informed consent.\n\nExclusion Criteria:\n\n1. current use of insulin;\n2. history of hypoglycemia unawareness; history of severe hypoglycemia requiring assistance within the last 5 years;\n3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l;\n4. history of lactic acidosis or diabetic ketoacidosis;\n5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper limit of normal at the time of enrollment;\n6. history of pancreatitis;\n7. cardiovascular disease including any of: a) systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 105 mmHg; b) peripheral vascular disease; c) left bundle branch block or second or third degree AV block; d) tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate; e) stenotic valvular heart disease; f) cardiomyopathy; g) history of heart failure; h) history of aortic dissection; i) documented history of angina or coronary artery disease; j) history of stroke or transient ischemic attack;\n8. history of any disease requiring continuous systemic glucocorticoid treatment;\n9. history of any major illness with a life expectancy of \\< 3 years;\n10. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity;\n11. excessive alcohol consumption (\\>14 alcoholic drinks per week in men and \\>7 alcoholic drinks per week in women);\n12. known hypersensitivity to insulin glargine, metformin, or any DPP-4 inhibitor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Hyperglycemia Relapse in the Experimental Group Compared to the Control Group","description":"Hyperglycemia relapse for primary outcome was defined as any one of:\n\n1. Capillary glucose \\>10 mmol/L on \\>/=50% of readings over 1 week;\n2. HbA1C \\>/=6.5%;\n3. use of diabetes drugs;\n4. fasting plasma glucose \\>/= 7.0 mmol/L;\n5. 2-hour postprandial plasma glucose \\>/=11.1 mmol/L on an oral glucose tolerance test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Severe Hypoglycemic Episodes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Drug-free Diabetes Remission","description":"Diabetes remission is defined as absence of hyperglycemia relapse","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Drug-free Normal Glucose Tolerance","description":"Normal glucose tolerance is defined as a FPG\\<6.1 mmol/L and a 2-hour plasma glucose \\<7.8 mmol/L on a 75 g oral glucose tolerance test","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"2.5"},{"groupId":"OG001","value":"-1.4","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.5"},{"groupId":"OG001","value":"-1.8","spread":"4.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Joint pain","Anxiety/depression","Infection","Atrial flutter","Vasovagal syncope"]}}}